Latest News - Allergan

Tuesday, February 27, 2018

US Appeals Board Denies Allergan's Attempts to End Mylan's Challenge to Restasis Patents

The US Patent Trial and Appeal Board (PTAB) denied a motion from Saint Regis Mohawk Tribe to terminate Mylan's challenge regarding six patents related to Allergan's dry-eye therapy Restasis (c…

Read the full story

Wednesday, February 07, 2018

Allergan's Profit Beats; Migraine Drug Succeeds in Key Study

Allergan on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study. The key data could ease some …

Read the full story

Tuesday, February 06, 2018

Allergan Names Matthew M. Walsh Executive Vice President and Chief Financial Officer

Allergan announced that Matthew M. Walsh has been appointed Executive Vice President and Chief Financial Officer. He will formally join Allergan later this month following a transition period from his…

Read the full story

Friday, February 02, 2018

Settling a Post-Buyout Hangover, Allergan Gives Teva a $700M Remedy

Teva and Allergan have put aside their differences -- and the result is an influx of cash that Teva badly needs, according to a report in FiercePharma. Wednesday, the former deal partners inked an …

Read the full story

Wednesday, January 17, 2018

FDA Issues Warning Letter to Imprimis for False and Misleading Claims

The FDA has issued a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about its products. The FDA stated that Imprimis made misleading…

Read the full story

Tuesday, January 16, 2018

Ackman looks to persuade judge $290M Allergan settlement is fair

Bill Ackman is going to try and hold onto a little cash on Tuesday. Lawyers for the embattled hedgie will appear before a federal judge in Los Angeles in an attempt to persuade him the $290 million se…

Read the full story

Wednesday, January 10, 2018

Don't Expect Restasis Generics Until At Least Next Quarter, Allergan CEO Says

Update on those Restasis generics Allergan investors have been seriously dreading: The company now believes they’re “unlikely” to arrive before the second quarter, CEO Brent Saunders…

Read the full story

Thursday, January 04, 2018

Allergan Plans to Eliminate More Than 1,000 Jobs as Part of Restructuring Initiative

Allergan on Wednesday unveiled in a regulatory filing that it plans to cut its labor force by more than 1,000 positions as part of a cost-cutting initiative. The drugmaker noted that &q…

Read the full story

Monday, October 30, 2017

Allergan Receives Approval for Ozurdex in China for the Treatment of Retinal Vein Occlusion

Allergan announced that it has received an imported drugs license from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment o…

Read the full story

Monday, October 16, 2017

Allergan Shares Slip As Judge Invalidates Patent on Top Selling Eye Drop

A federal judge struck down patents protecting one of Allergan’s top-selling drugs, sending shares in the company down nearly 5 percent, according to a report in the Financial Times. The Texa…

Read the full story

Wednesday, October 04, 2017

U.S. House Committee Launches Probe of Allergan Patent Deal

A U.S. House of Representatives committee launched a probe into drugmaker Allergan's deal to transfer some of its patents to a Native American tribe to shield them from review, according to a repo…

Read the full story

Monday, October 02, 2017

Shire Alleges Allergan Blocked Drug From Medicare Contracts

Shire filed an antitrust suit against Allergan alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug, ac…

Read the full story

Tuesday, September 26, 2017

Allergan Authorizes New $2 Billion Share Repurchase Program

Allergan announced that the company's board of directors has authorized a new $2 billion share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend…

Read the full story

Monday, September 18, 2017

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan caused a lot of hand-wringing in the biotech community and excitement among patent lawyers, when the drugmaker announced it would transfer patents for Restasis, Allergan's longstandi…

Read the full story

Friday, September 08, 2017

Allergan Partners With Indian Tribe to Protect Restasis Drug Patents

In an unusual strategy to protect Restasis from generic competition, Allergan announced that is it has sold the drug's patents to an Indian tribe in upstate New York. Allergan and the Saint Reg…

Read the full story
Load More